Leaving Lytic Lesions-Is There New Role for Radiation in Multiple Myeloma in the CAR T Era?

Pract Radiat Oncol. 2022 Sep-Oct;12(5):367-369. doi: 10.1016/j.prro.2022.05.002.

Authors

Hazim S Ababneh¹, Noopur S Raje², Andrew J Yee², Chirayu G Patel³

Affiliations

¹ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
² Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
³ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: [email protected].

PMID: 36058616
DOI: 10.1016/j.prro.2022.05.002

No abstract available

Publication types

Editorial

MeSH terms

Humans
Immunotherapy, Adoptive
Multiple Myeloma* / radiotherapy
Receptors, Chimeric Antigen*

Substances

Receptors, Chimeric Antigen